Bayer logo
US MEDICAL AFFAIRS

Publications

Publications

Home/Publications

We invite you to explore Bayer-supported publications. This library is not intended to serve as a comprehensive repository of all publications. Publications not supported by Bayer are not included. Access to the full text of publications may depend on journal access rights.

To help narrow down your search, choose the relevant tags and click Apply. Selecting multiple tags will narrow your results.

Last updated September 16, 2025.

Types of Enhancements Available

Audio Icon
Audio
Infographic Icon
Infographic
Plain language summary icon
Plain Language Summary
Video icon
Video
Digital enhancements icon
Other

To help narrow down your search, select the relevant filters from the dropdowns and Click Apply

Hold down Ctrl key on keyboard to select multiple years

Total available publications: 339    

Filtered results: 52

Cost-effectiveness analysis of regorafenib dose optimization for refractory metastatic colorectal cancer

Weinrib R., et al. Oncology and Therapy. 2025.

Bekaii-Saab T.; Cho S.K.; Hocum B.; Grossman J.; Appukkuttan,
READ
EMAIL

Sequential Treatment with Regorafenib and Trifluridine/Tipiracil ± Bevacizumab in Refractory Metastatic Colorectal Cancer in Community Clinical Practice in the USA

Ahn D.H., et al. Cancers. 2025;17(6):969.

Ahn D.H.; Bekaii-Saab T.S.; Yuan C.; Kurtinecz M.; Pan X.; Vassi,
READ
EMAIL

Stanniocalcin 1 in Patients with Refractory Colorectal Cancer Treated with Regorafenib: A Post Hoc Biomarker Analysis of the TEXCAN and CORRECT Trials

Vienot A., et al. Cancer Research Communications. 2025;5(2):287–294.

Vienot A.; Vernerey D.; Bouard A.; Klajer E.; Kim S.; Tournigand,
READ
EMAIL

Effect of Regorafenib in Delaying Definitive Deterioration in Health-Related Quality of Life in Patients with Advanced Cancer of Three Different Tumor Types

Hofheinz RD, et al. Cancer Manag Res. 2021;13:5523-5533.

Hofheinz RD,
READ
EMAIL

NTRK fusion in Japanese colorectal adenocarcinomas

Yamashiro Y, et al. Sci Rep. 2021;11(1):5635.

Yamashiro Y,
READ
EMAIL

18F-FDG-PET/CT as an imaging biomarker for regorafenib efficacy in metastatic colorectal cancer
(JACCRO CC-12)

Nakamura M, et al. Oncology and Therapy. 2021;9(2):635-645.

Nakamura M,
READ
EMAIL

Preference criteria for regorafenib in treating refractory metastatic colorectal cancer are the small tumor burden, slow growth and poor/scanty spread

Unable to trace info

Hsu, HC., Huang, K.C., Chen, W.S., Jiang, J.K., Yang, S.H., Wang,
READ
EMAIL

Real-world evidence of the safety and effectiveness of regorafenib in Taiwanese patients with metastatic colorectal cancer: CORRELATE Taiwan

Yeh K, et al. J Formos Med Assoc. 2021;120(11): 2023-2031

Yeh K,
READ
EMAIL

FOLFIRINOX-R study design: a phase I/II trial of FOLFIRINOX plus regorafenib as first line therapy in patients with unresectable RAS-mutated metastatic colorectal cancer

Adenis A, et al. BMC Cancer. 2021;21(1):564.

Adenis A,
READ
EMAIL

A Phase I dose-escalation study of regorafenib in combination with trifluridine/tipiracil in subjects with metastatic colorectal cancer who have progressed after standard therapy (REMETY)

Moehler M, et al. Future Oncology. 2021;17(25):3309-3319.

Moehler M,
READ
EMAIL
Bayer logo

You are encouraged to report side effects or quality complaints of products to the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088. For Bayer products, you can report these directly to Bayer by clicking here.

 

This site provides access to balanced and evidence-based medical information related to our therapeutic areas of focus and is intended to serve as a medical resource for US HCPs. This may include investigational compounds or investigational new uses of FDA-approved Bayer products. The information provided is not intended to be promotional or provide medical advice. Please refer to the full Prescribing Information for approved indications, contraindications, warnings and precautions, and adverse events.

 

© 2026 Bayer. Bayer and the Bayer Cross are registered trademarks of Bayer.

Site last updated 02/2026

Follow Us

Twitter (X) icon Twitter (X) icon
YouTube icon YouTube icon
LinkedIn icon LinkedIn icon
US Medical Affairs QR Code